Introduction
This short article will not attempt to detail every treatment possibility in each of the 150 or so interstitial lung diseases. Rather it will highlight some of the principles which, if followed, improve management. It will also highlight some of the continuing problems in this very difficult area of respiratory medicine.
The importance of establishing a correct diagnosis It might appear self evident that treatment can only be suitable when the correct diagnosis has been established. In practice, this principle is often ignored. The probable explanation to this is that certain interstitial diseases are a great deal more common than others and it is tempting to be satisfied with a clinical likelihood rather than objective proof. However as the student said to the examiner when chastised for making a diagnosis because it was too rare, he replied, 'rare diseases would occur more often if they were diagnosed more frequently'! In particular because of its common occurrence in young people, sarcoidosis is often diagnosed and treated on insufficient evidence and only later, when the patient has deteriorated seriously is the correct diagnosis apparent. This has important therapeutic implications if, for example, the patient in fact suffered from alveolar proteinosis where a large volume lung lavage can be life-saving.
The second reason why a correct diagnosis is important is that the natural history of different diseases varies strikingly and knowledge of this is essential for logical planned treatment. For example some 70% of patients with sarcoidosis resolve spontaneously within about 2 years while 50%o of patients with cryptogenic fibrosing alveolitis are dead within 4 or 5 years. The argument is always put forward that since corticosteroids are the only treatment available an empirical trial is a practical and simple way to proceed. This policy in practice leads physicians into great difficulties. When the patient has a doubtful response, the physician is then in a quandary with regard to the diagnosis and so no prognostic indications can be given to the patient or their relatives. In certain instances other specific treatments are available (e.g. large volume lavage in alveolar proteinosis and perhaps hormone treatment in lymphangioleiomyomotosis, plasma pheresis in some types of pulmonary haemorrhage and high dose cotrimoxazole in pneumocystis pneumonia).
Further, where there is not too much irreversible fibrosis, immunosuppressive drugs such as cyclophosphamide or azathioprine have been shown to be a real alternative when corticosteroids fail; but such drugs have serious potential side effects and should only be used when the condition is appropriate.
A plan of monitoring response
Responses to treatment are often at best partial so that a systematic plan should be made not only with regard to drug dosage but also as to how the response is to be monitored. The most practical current tools include systematic semi-quantitative grading of the patients' symptoms, the chest radiograph and standard lung function tests. The latter should include both lung volume and transfer factor measurements for carbon monoxide because these two measurements do not always change in parallel. Our own practice is also to undertake serial standardized exercise tests with blood gas measurements, but whether this gives much additional information is still to be examined formally. We also include a 6-minute walking test as well as the patient's own assessment of breathlessness on a questionnaire and a 10 cm analogue scale. These records are simple to keep and are probably more accurate than simple narrative statements. However formal validation has not yet been undertaken.
Plan of dosage schedule
When corticosteroids are used (and irrespective of the disease) it is probably reasonable to start with a fairly large dose. Our normal practice is to use about 40 mg of prednisolone in sarcoidosis (where the disorder tends to respond fairly easily) and 60 mg in cryptogenic fibrosing alveolitis where the condition is usually less responsive. This relatively high dose is used for about 4 weeks to achieve optimal improvement in as many parameters as possible. Having achieved maximum response for an individual patient (which is often far from complete resolution of disease) the dose can be titrated to the lowest which maintains optimal improvement. We label (green by our code) the X-ray showing maximum improvement so that this film can be compared with subsequent ones and we believe it is the easiest way of detecting insidious deterioration which may occur so slowly that it cannot be detected by comparing any two sequential films.
In sarcoidosis a number of patients can be maintained on an alternate day regime. However about a third of our patients deteriorate on such a regime and a daily dose is then used. We give the whole dose once a day in the morning.
Special considerations in individual disorders Sarcoidosis
Indications for treatment of interstitial pulmonary lesions in sarcoidosis present special problems in relation to the natural history of the condition. Most authors agree that overall some 70%o of all patients with interstitial radiographic infiltrates will resolve spontaneously and without treatment within about 2 years. Others remit more slowly over 2-8 years but the longer resolution takes the greater the chances of some irreversible scarring developing. This in itself may be unimportant in some cases although secondary infection from anatomical distortion or aspergillomas in disorganized lung may be responsible for both morbidity and mortality. The physician is faced with a dilemma because on the one hand the treatment is often unnecessary, but if delayed too long, the disease may compromise both health and even life. Cases presenting with interstitial infiltrates without erythema nodosum or hilar node enlargement especially in older individuals (over the age of about 30 years) are probably at special risk of developing progressive disease.
Formal clinical trials have so far failed to demonstrate definite benefits of steroids mainly because they have not been designed bearing in mind the natural history of the sub-populations studied. Treatment for the time being thus has to be based on a logical, if unproven basis. Our present policy is outlined, recognizing that many do not agree and that we, like others, have no proof that the policy we have adopted is correct.
Unless there are over-riding indications for treatment (e.g. rapid deterioration of breathlessness or special extra-thoracic involvement) we follow patients for about 1-2 years from their first presentation but do not treat with steroids, to allow them a Treatment of interstitial lung disease maximum opportunity of resolving spontaneously. If however the radiograph fails to improve over this period, our principle is to start corticosteroid treatment even in the absence of symptoms or abnormal lung function tests. The policy is thus to avoid treating patients who will resolve spontaneously but to intervene before irreversible changes have developed. In practice, this balance point is hard to achieve but the principle is clear.
Once treatment is started we aim to obtain maximum improvement in symptoms, chest radiographic appearances, lung volumes and carbon monoxide diffusion capacity (DLCO) and to maintain this on the lowest possible dose of steroids. In practice this is achieved on a maintenance alternate day regime in about two-thirds of our patients using between 10 and 15 mg of prednisolone. In the remaining third a daily regimen on about the same dose is necessary.
We maintain patients on a minimal dose for about 1 year then and attempt to stop-always explaining to the patient that treatment may have to be restarted if the X-ray deteriorates.
Relapse may not occur immediately on withdrawal of corticosteroids so patients have to be watched particularly carefully over the years following discontinuation of therapy. We have seen late relapses occurring after 3 or 4 years.
Relapse of sarcoidosis while under treatment is so often due to two correctable factors. The patient may not be taking the prescribed dose or indeed any steroids at all, or the doctor may be continuing to prescribe an arbitrary maintenance dose when the disease is obviously relapsing. Individual titration of the dose against maximum response is a logical policy.
Clearly validation of a particular treatment policy in sarcoidosis is very difficult in view of the widely varying course of disease, its often slow rate ofchange and the inadequacy of accurate markers of activity.
However it should be remembered that once fibrosis has developed the consequences are usually compromising and may be directly or indirectly lethal.
Cryptogenic fibrosing alveolitis
Management of cryptogenic fibrosing alveolitis in some ways presents fewer problems but in others is more difficult. The decision when to treat is easier because the outlook is so much worse (50o of patients dead 4-5 years); thus early treatment to obtain maximum benefit is less controversial. However response to steroids is less frequent and in responders is usually only partial, so that titration of the drug dosage is more difficult. We have shown that the factors tending to predict a better response to steroids include younger patients, women, less radiographic abnormality, shorter duration of disease combined with a more severe reduction of forced vital capacity (less than 66% predicted In spite of these difficulties patients with these disorders have a serious long-standing problem which if mishandled will lead to compromised health and in some instances will shorten their lives. Thus the most careful assessment is mandatory if any progress is to be made.
